Alnylam Pharmaceutical's latest animal study may ease safety concerns over its experimental drugs derived from RNA interference, the company said. Researchers found that Alnylam's gene-blocking molecules were able to block about 80% of the genes' effects on mice without disturbing a critical cell regulation system.

Full Story:

Related Summaries